Epidemiology of liver diseases:global disease burden and forecasted research trends  

作　　者：Jia Xiao Fei Wang Yuan Yuan Jinhang Gao Lu Xiao Chao Yan Feifei Guo Jiajun Zhong Zhaodi Che Wei Li Tian Lan Frank Tacke Vijay H.Shah Cui Li Hua Wang Erdan Dong 

机构地区：[1]Department of Gastroenterology,Qingdao Central Hospital,University of Health and Rehabilitation Sciences,Qingdao 266071,China [2]Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment,Zhuhai Hospital Affiliated with Jinan University,Zhuhai 510630,China [3]Division of Gastroenterology,Seventh Affiliated Hospital of Sun Yat-sen University,Shenzhen 518107,China [4]School of Biological Sciences,Jinan University,Guangzhou 519070,China [5]Aier Institute of Ophthalmology,Central South University,Changsha 410015,China [6]Lab of Gastroenterology and Hepatology,West China Hospital,Sichuan University,Chengdu 610041,China [7]Clinical Medicine Research Institute and Department of Metabolic and Bariatric Surgery,the First Affiliated Hospital of Jinan University,Guangzhou 510630,China [8]Faculty of Pharmaceutical Sciences,Toho University,Chiba Tokyo 143-8540,Japan [9]Department of Hepatology and Gastroenterology,Charité-Universitätsmedizin Berlin,Campus Virchow-Klinikum and Campus CharitéMitte,Berlin 13353,Germany [10]Division of Gastroenterology and Hepatology,Mayo Clinic,Rochester MN 55905,USA [11]Department of Health Sciences,National Natural Science Foundation of China,Beijing 100085,China [12]Department of Oncology,The First Affiliated Hospital,Institute for Liver Diseases of Anhui Medical University,Hefei 230032,China [13]Inflammation and Immune Mediated Diseases Laboratory of Anhui Province,Anhui Medical University,Hefei 230032,China [14]Research Center forCardiopulmonary Rehabilitation,Universityof Health and Rehabilitation Sciences Qingdao Hospital(Qingdao Municipal Hospital),Schoolof Health andLifeSciences,Universityof Health and Rehabilitation Sciences,Qingdao 266071,China [15]Department of Cardiology and Institute of Vascular Medicine,Peking University Third Hospital,State Key Laboratory of Vascular Homeostasis and Remodeling,Peking University,Beijing 100191,China

出　　处：《Science China(Life Sciences)》2025年第2期541-557,共17页中国科学(生命科学英文版)

基　　金：supported by National Natural Science of Foundation(82122009,82225008,82322011,and U23A20401);Shenzhen Medical Research Fund(B2302007);Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2021-I2M-5-003);Key Projects of the Chinese Academy of Engineering;Strategic research on the development of rehabilitation medicine in the new era(2023–33–19);Cell Ecology Haihe Laboratory Unveiling and Leading Projects(HH22KYZX0047);Shenzhen Science and Technology Program(JCYJ20210324123212033);Guangdong Basic and Applied Basic Research Foundation(2021B1515120069)。

摘　　要：We assessed the global incidence,mortality,and disability-adjusted life years(DALYs)associated with various liver diseases,including alcohol-related liver disease(ALD),hepatitis B/C virus infections(HBV or HCV),liver cancer,metabolic dysfunction-associated steatotic liver disease(MASLD),and other chronic liver diseases,from the 2019 Global Burden of Disease study.Additionally,we analyzed the global trends in hepatology research and drug development.From 2000 to 2019,prevalence rates increased for ALD,MASLD and other liver diseases,while they decreased for HBV,HCV,and liver cancer.Countries with a high socio-demographic index(SDI)exhibited the lowest mortality rates and DALYs.The burden of liver diseases varied due to factors like sex and region.In nine representative countries,MASLD,along with hepatobiliary cancer,showed highest increase in funding in hepatology research.Globally,the major research categories in hepatology papers from 2000 to 2019 were cancer,pathobiology,and MASLD.The United States(U.S.)was at the forefront of hepatology research,with China gradually increasing its influence over time.Hepatologists worldwide are increasingly focusing on studying the communication between the liver and other organs,while underestimating the research on ALD.Cancer,HCV,and MASLD were the primary diseases targeted for therapeutic development in clinical trials.However,the proportion of new drugs approved for the treatment of liver diseases was relatively low among all newly approved drugs in the U.S.,China,Japan,and the European Union.Notably,there were no approved drug for the treatment of ALD in the world.

关 键 词：liver disease disease burden GBD estimate research trend drug development 

分 类 号：R575[医药卫生—消化系统]